Generic Drug Enforcement Act Clause Samples
POPULAR SAMPLE Copied 7 times
Generic Drug Enforcement Act. To the Knowledge of Agouron, none of the individuals set forth on Exhibit 3.2(z) have ever (i) been employed or contracted for services by Agouron, or (ii) contributed to the development of any of the Investigational Compounds.
Generic Drug Enforcement Act. Supplier has not used and will not use in the manufacture of the BX7, Validation Batches or the API Compound in any capacity the services of any person, including any firm or individual, debarred or subject to debarment under the Generic Drug Enforcement Act of 1992, amending the Act at 21 U.S.C. 335a. Supplier agrees to notify Adolor immediately in the event any person providing services to Supplier relating to this Agreement is debarred or becomes subject to debarment.
Generic Drug Enforcement Act. Neither Noven, its Affiliates nor any of their respective officers, directors, employees, agents or consultants have been charged with or convicted under federal law for conduct relating to the development or approval of, or otherwise relating to the regulation of, any product under the Generic Drug Enforcement Act of 1992 or any other relevant statute, law or regulation. Neither Noven, its Affiliates nor any of their respective officers, directors, employees, agents or consultants has been debarred under Section 306(a) or Section 306(b) of the FDC Act, nor convicted of any offense required to be listed under Section 306(k)(2) of the FDC Act.
Generic Drug Enforcement Act. Neither Purchaser, it Affiliates nor any of their respective officers, directors, employees, agents or consultants have been charged with or convicted under federal law for conduct relating to the development or approval of, or otherwise relating to the regulation of, any product under the Generic Drug Enforcement Act of 1992 or any other relevant statute, law or regulation.
Generic Drug Enforcement Act. Neither P&GP, its Affiliates nor any of their respective officers, directors, employees, agents or consultants have been charged with or convicted under federal law for conduct relating to the development or approval of, or otherwise relating to the regulation of, any product under the Generic Drug Enforcement Act of 1992 or any other relevant statute, law or regulation. Neither P&GP, its Affiliates nor any of their respective officers, directors, employees, agents or consultants has been debarred under Section 306(a) or Section 306(b) of the FDC Act, nor convicted of any offense required to be listed under Section 306(k)(2) of the FDC Act.
Generic Drug Enforcement Act. 37 3.3 Representations and Warranties of Warner-Lambert and Merger Sub . . . . . . . . . . . . . . . . . . . . . . . 37 (a) Organization . . . . . . . . . . . . . . . . . . . . 37 (b) Corporate Authorization . . . . . . . . . . . . . . 37 (c) Non-Contravention . . . . . . . . . . . . . . . . . 37 (d) No Business Activities . . . . . . . . . . . . . . . 38 ARTICLE IV
Generic Drug Enforcement Act. PII has not used and will not use in the manufacture of Drug Product in any capacity the services of any person, including any firm or individual, debarred or subject to debarment under the Generic Drug Enforcement Act of 1992, amending the Act at 21 U.S.C. 335a. PII agrees to notify Adolor immediately in the event any person providing services to PII relating to this Agreement is debarred or becomes subject to debarment.